RxDoctor Payments Data

Tarandeep Chahal, MD

Internal Medicine · Port Orchard, WANPI 1972956472

Payments from drug & device makers

$8,541in general payments, 2019–2025

Across 468 payments — averaging $18.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • Novo Nordisk$1K
  • Boehringer Ingelheim$818
  • Bayer$614
  • AstraZeneca$527
  • Novartis$468
  • plus $4K from 50 others

What the payments were for

  • Food & beverage$8,541100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,541 in reported general payments places this provider in the 95th percentile of 2,038 internal medicine providers in Washington.

See all internal medicine providers in Washington

Medicare billing

Part B allowed, 2024
$347,820
Medicare patients
655
Services billed
6,263

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin77$110,029
OzempicSemaglutide63$109,541
EliquisApixaban80$99,456
XareltoRivaroxaban47$73,071
MounjaroTirzepatide40$64,457
FarxigaDapagliflozin Propanediol29$33,867
TrulicityDulaglutide22$29,218
RybelsusSemaglutide13$26,595
MyrbetriqMirabegron15$19,161
Repatha SureclickEvolocumab13$16,732
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$12,411
SynjardyEmpagliflozin/Metformin Hcl11$6,744
Atorvastatin Calcium531$5,963
Duloxetine Hcl135$5,236
Spinosad22$5,229

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,102$136,13676 claims
Boehringer IngelheimJardiance, Synjardy$818$116,77388 claims
PfizerEliquis$337$99,45680 claims
Lilly USA, LLCMounjaro, Trulicity$440$93,67562 claims
Johnson & JohnsonXarelto$179$73,07147 claims
AstraZenecaFarxiga$527$33,86729 claims
GSKTrelegy Ellipta$127$12,41121 claims
AbbVieSynthroid$141$2,94732 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,038 internal medicine providers in Washington.

Other internal medicine in Port Orchard

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →